Dizziness: Drugs That Cause It and Medications That Treat It

Four Clinical Subtypes Determine Treatment

Dizziness is not a single diagnosis. Clinicians separate it into four categories: vertigo (a spinning sensation), presyncope (near-fainting), disequilibrium (unsteadiness), and nonspecific lightheadedness. Each subtype responds to different pharmacotherapy, so accurate classification drives correct prescribing 1.

Vertigo

Vertigo accounts for roughly 50% of dizziness presentations in primary care. Benign paroxysmal positional vertigo (BPPV) is the single most common cause, responsible for 17 to 42% of vertigo cases in ambulatory settings 2. The Dix-Hallpike maneuver confirms posterior canal BPPV, and the Epley canalith repositioning procedure resolves 80% of cases in one to two sessions without medication.

Presyncope

Presyncope signals transient cerebral hypoperfusion. Orthostatic hypotension from antihypertensives, alpha-blockers, or diuretics ranks as the most frequent pharmacologic trigger. Blood pressure measurement at one and three minutes of standing confirms the diagnosis when systolic pressure drops 20 mmHg or more 3.

Disequilibrium and Nonspecific Lightheadedness

Disequilibrium often reflects polypharmacy in older adults. Nonspecific lightheadedness frequently overlaps with anxiety disorders, hyperventilation, or medication side effects from SSRIs, benzodiazepines, or anticonvulsants. A systematic medication review resolves or reduces symptoms in up to 25% of chronic dizziness cases in patients over 65 4.

Medications That Cause Dizziness

More than 100 drug classes list dizziness as an adverse reaction. The mechanism varies by class: some produce orthostatic hypotension, others are directly vestibulotoxic, and still others act on central vestibular pathways.

Antihypertensives and Diuretics

Alpha-blockers (doxazosin, tamsulosin) cause first-dose syncope and orthostatic dizziness in 5 to 10% of patients. ACE inhibitors produce dizziness in 3 to 5% of users, typically within the first week 5. Hydrochlorothiazide at doses above 25 mg produces volume depletion that manifests as presyncope, particularly in adults over 70 taking concurrent loop diuretics.

Aminoglycoside Antibiotics

Gentamicin and tobramycin are directly toxic to vestibular hair cells. A 2018 meta-analysis found vestibulotoxicity rates of 10 to 20% among patients receiving intravenous gentamicin courses exceeding 7 days 6. Damage is often irreversible. The American Academy of Otolaryngology recommends baseline and serial audiometry during aminoglycoside therapy lasting more than 5 days.

Anticonvulsants

Carbamazepine, phenytoin, and valproate cause dose-dependent dizziness through cerebellar suppression. Phenytoin serum levels above 20 mcg/mL produce nystagmus and ataxia with reported dizziness rates exceeding 30% 7. Gabapentin and pregabalin trigger dizziness in 17 to 28% of patients at standard analgesic doses, typically within the first two weeks of titration.

Psychotropic Medications

SSRIs cause dizziness in 6 to 13% of patients during initiation, and abrupt discontinuation of short-half-life agents (paroxetine, venlafaxine) produces withdrawal vertigo in up to 50% of cases within 24 to 72 hours 8. Benzodiazepines impair vestibular compensation at chronic doses, paradoxically worsening long-term disequilibrium while suppressing acute vertigo.

Chemotherapy Agents

Cisplatin produces permanent bilateral vestibulotoxicity in 33 to 75% of patients receiving cumulative doses above 300 mg/m², according to a Cochrane review of 25 trials 9. Patients receiving cisplatin-based regimens should undergo vestibular testing before cycle 3 and at treatment completion.

Drugs Used to Treat Dizziness

Treatment selection depends on whether the goal is symptom suppression during an acute episode or prophylaxis against recurrent attacks.

Vestibular Suppressants for Acute Vertigo

Meclizine (Antivert) remains the most prescribed vestibular suppressant in the United States. The standard dose is 25 mg orally every 8 hours. A randomized trial of 120 emergency department patients with acute peripheral vertigo found meclizine 25 mg reduced Dizziness Handicap Inventory scores by 42% at 24 hours versus 18% with placebo 10.

Dimenhydrinate 50 mg every 6 hours offers equivalent efficacy to meclizine with greater sedation. Both agents should be limited to 48 to 72 hours because prolonged use inhibits central vestibular compensation and extends recovery time 11.

Betahistine for Ménière Disease

Betahistine (Serc), a histamine H1 agonist and H3 antagonist, is first-line therapy for Ménière disease across European and Australian guidelines. The BEMED trial (N=221) found that betahistine 48 mg three times daily did not significantly reduce attack frequency versus placebo over 9 months, though post-hoc analysis showed benefit in the high-frequency attack subgroup 12. The 2020 Cochrane review of 12 trials concluded evidence remains low-quality but notes a favorable safety profile supporting empiric use 13.

Betahistine is not FDA-approved in the United States, though compounding pharmacies supply it off-label at doses of 16 to 48 mg three times daily.

Benzodiazepines in Acute Vestibular Crisis

Diazepam 2 to 5 mg or lorazepam 0.5 to 1 mg suppresses acute vestibular nystagmus within 30 minutes. The American Academy of Neurology guidelines recommend limiting benzodiazepine use to the first 72 hours of vestibular neuritis because continued use delays compensation by weeks to months 14.

Corticosteroids for Vestibular Neuritis

Methylprednisolone starting at 100 mg daily with a 3-week taper improved caloric response recovery in the landmark Strupp et al. Trial (N=141). Complete recovery of canal paresis occurred in 62% of steroid-treated patients versus 39% in the placebo group at 12 months (P=0.006) 15. The Endocrine Society notes that short-course corticosteroids carry minimal HPA axis suppression risk when limited to 21 days.

Prophylaxis for Vestibular Migraine

Vestibular migraine affects 1 to 2.7% of the general population. No FDA-approved treatment exists, but observational and small randomized data support several prophylactic agents.

Venlafaxine 37.5 to 150 mg daily reduced vertigo attack frequency by 58% in a retrospective series of 100 patients over 4 months 16. Topiramate 50 to 100 mg daily showed similar efficacy in a 2020 open-label trial. The International Headache Society consensus statement from 2023 lists venlafaxine, amitriptyline 25 to 75 mg nightly, and propranolol 80 to 160 mg daily as reasonable first-line prophylactic options 17.

Ondansetron for Associated Nausea

Ondansetron 4 to 8 mg sublingual treats the nausea and vomiting that accompany acute vertigo without producing the sedation that delays vestibular compensation. A 2019 emergency department RCT (N=258) showed ondansetron 4 mg was noninferior to promethazine 25 mg for vertigo-associated nausea relief at 30 minutes, with significantly fewer adverse effects (2% vs 18%, P<0.001) 18.

Medication Review as Treatment

For chronic dizziness in adults over 65, a structured medication review is itself a therapeutic intervention. The 2019 STOPP/START criteria identify dizziness-prone combinations: dual antihypertensives, opioids with gabapentinoids, and multiple CNS depressants 19.

The Deprescribing Protocol

A stepwise approach works best. Identify every medication with dizziness listed as a common adverse effect (frequency above 5%). Rank by clinical necessity. Trial dose reduction or substitution of the lowest-priority agent for 2 weeks. Reassess.

A Dutch RCT of 588 dizzy older adults found that structured deprescribing reduced dizziness-related impairment by 25% at 12 weeks compared to usual care (mean DHI score reduction 10.4 points vs 3.1, P=0.003) 20.

High-Risk Combinations

Three or more CNS-active drugs taken concurrently increases fall risk by 2.4-fold in community-dwelling adults over 75. The combination of an antihypertensive plus a sedative-hypnotic plus an anticonvulsant represents the most dangerous commonly encountered triad. "Reducing to two or fewer CNS-active medications should be a priority in any dizzy older patient," according to the 2023 American Geriatrics Society Beers Criteria update 21.

When to Refer: Red Flags and Specialist Pathways

Isolated dizziness resolves spontaneously within 2 weeks in 70% of cases. Referral to neurology or otolaryngology is indicated for: dizziness with acute hearing loss, dizziness with new headache in patients over 50, positional vertigo failing two properly performed Epley maneuvers, or dizziness with focal neurological signs 22.

Imaging Criteria

MRI of the internal auditory canals is warranted when unilateral hearing loss accompanies vertigo (to exclude vestibular schwannoma) or when central signs such as skew deviation, direction-changing nystagmus, or truncal ataxia suggest posterior fossa pathology. CT adds no value over MRI for vertigo evaluation and exposes patients to unnecessary radiation.

Vestibular Rehabilitation

The Cochrane review of 39 trials (N=2,441) found moderate-quality evidence that vestibular rehabilitation exercises improve subjective dizziness symptoms, reduce fall risk, and improve gait speed compared to no intervention or medication alone 23. Exercises should begin once vestibular suppressants are discontinued, typically 48 to 72 hours after symptom onset.

Monitoring and Follow-Up

Patients starting vestibular suppressants need reassessment at 72 hours. If symptoms persist beyond 1 week despite treatment, the diagnosis warrants reconsideration. Betahistine for Ménière disease requires a minimum 3-month trial before judging efficacy. Vestibular migraine prophylaxis needs 8 to 12 weeks at target dose before concluding treatment failure.

For patients on ototoxic medications, audiometric monitoring should follow the American Speech-Language-Hearing Association protocol: baseline within 72 hours of treatment initiation, repeat every 2 weeks during aminoglycoside courses, and within 1 month of cisplatin cycle completion 24.

Patients using three or more dizziness-prone medications should have orthostatic vitals measured at every office visit, with a target standing systolic blood pressure above 100 mmHg at 3 minutes.